Recent genomic studies have confirmed the presence of tumor-harboring somatic mutations and alterations of specific genes in individuals with LUAD, most notably mutation of the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), which paved the way for novel classes of drugs known as targeted kinase inhibitors. Here, ALK is linked to neoplasm.